Dear Sirs,
We report four cases of severe COVID-19 in male patients aged 50–70 with the combination of central and peripheral nervous system disorders occurring unexpectedly late after the first symptoms. Patients had comorbidities and were admitted for acute respiratory distress syndrome due to a proven SARS-CoV-2 infection. All required mechanical ventilation, among whom one needed an extracorporeal membrane oxygenation support.
Several acute neurological syndromes have been associated with SARS-CoV-2 infection, including anosmia and ageusia [1, 2], meningoencephalitis [3, 4], acute hemorrhagic necrotizing encephalopathy [5], axonal or demyelinating polyradiculoneuropathy [6,7,8], polyneuritis cranialis [8]. Like in most of the viral infections that involve nervous system, these manifestations occurred within the first ten days after infectious symptoms. Further away from the onset of the disease, when sedation and neuromuscular blocker were withheld, 67% of the patients with severe COVID-19 develop encephalopathy including prominent agitation, confusion and corticospinal tract signs [9].
In our cases neurological manifestations were detected after mechanical ventilation weaning and extubation (Fig. 1). They consisted of miscellaneous symptoms such as confusion, cognitive dysfunction (memory deficit, frontal syndrome), psychiatric disorders (paranoid delusion, hallucinations), weakness, pyramidal signs, dysautonomia, swallowing dysfunction, vertical supranuclear eye palsy, upper limbs myoclonus, fasciculation and focal muscle atrophy (Table 1). To note, before admission to intensive care unit, patients had no neurological symptom, except for anosmia or ageusia in two of them. One patient had a small acute sub-cortical ischemic stroke on brain MRI. Cerebrospinal fluid (CSF) analysis showed a normal cell count and a moderate increase of protein level in the up to 80 mg/L in two cases. RT-PCR and IgM for SARS-CoV-2 in the CSF were negative in all patients. On EEG, non-rhythmic frontal slow waves were observed in two patients. Three patients had electrophysiological features of acute motor demyelinating polyradiculoneuropathy with delayed distal latencies and F-waves, slowed conduction velocities and conduction blocks (Supplementary Table). The remaining patient had lower motor neuron features in both the upper and lower limbs. Two patients had an additional decrease of sensorimotor potential amplitude compatible with a critical illness neuropathy. Swallowing and eye movement improved within the first week. Given the persistent muscle weakness and electromyographic features suggesting a post-infectious mechanism, an immunoglobulin therapy was introduced for 5 days. Psychiatric symptoms, cognitive impairment and dysautonomia improved thereafter, but myoclonus and motor weakness of the upper limbs persisted 3 weeks after discharge. Three patients required prolonged rehabilitation in a specialized center.
We describe here delayed mixed central and peripheral disorders as a complication of severe COVID-19. It combines acute encephalopathy and motor demyelinating polyradiculoneuropathy or diffuse lower motor neuron involvement. Persistent cognitive and motor deficit might result from a critical illness, but neurological features differ from critical illness-related encephalopathy and neuropathy. Critical illness-related neuropathy is characterized by a bilateral, symmetric, axonal sensorimotor polyneuropathy resulting in an areflexic tetraplegia, without dysautonomia or cranial nerves palsy. In our patients, clinical and neurophysiological features of peripheral nervous system involvement could partly reflect critical illness neuropathy but most of them are not expected in this context and are thus more likely linked to COVID-19. Abnormal eye movement, swallowing dysfunction and action myoclonus are unusual in critical illness-related encephalopathy and might rather result from COVID19-related brainstem dysfunction in our patients.
Our study suggests a wider spectrum than previously reported of neurological manifestations associated with COVID-19 and further suggests that patients with severe forms of COVID-19 should be systematically screened for neurological complications.
References
Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. JAMA Neurol, China
Politi LS, Salsano E, Grimaldi M (2020) Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (covid-19) and anosmia. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2020.2125
Moriguchi T, Harii N, Goto J et al (2020) A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Intern J Diseases 12:19–71. https://doi.org/10.1016/j.ijid.2020.03.062
Chaumont H, Etienne P, Roze E et al (2020) Acute meningoencephalitis in a patient with COVID-19. Revue Neurol 35(3):7–87. https://doi.org/10.1016/j.neurol.2020.04.014
Poyiadji N, Shahin G, Noujaim D et al (2020) COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 20:11–87. https://doi.org/10.1148/radiol.2020201187
Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med NEJMc 20:9–91. https://doi.org/10.1056/NEJMc2009191
Zhao H, Shen D, Zhou H et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30109-5
Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S et al (2020) Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology 20:20–597. https://doi.org/10.1212/WNL.0000000000009619
Helms J, Kremer S, Merdji H et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med NEJMc 20:20–597. https://doi.org/10.1056/NEJMc2008597
Acknowledgments
The authors thank Yves Chaudière for his language expertise.
Funding
No funding.
Author information
Authors and Affiliations
Contributions
HC: acquisition, analysis, and interpretation of data and drafting the manuscript; AS-G: acquisition of data and drafting the manuscript; FM: acquisition of data; CC: acquisition of data; GJ: revising the manuscript, analysis, and interpretation of data; MC: acquisition, analysis and interpretation of data and revising the manuscript; ER: drafting and revising the manuscript, analysis, and interpretation of data; AL: acquisition, analysis and interpretation of data, drafting and revising the manuscript.
Corresponding author
Ethics declarations
Availability of data and material
Not applicable.
Code availability
Not applicable.
Consent for publication
Patient’s consent has been obtained.
Conflicts of interest
Dr. Chaumont reports having received travel grant from PEPS development, Roche and Pfizer. Dr. Roze reports served on scientific advisory boards for Orkyn, Aguettant, Merz-Pharma; received honoraria for speeches from Orkyn, Aguettant, Merz-Pharma, Medday-Pharma, Everpharma, International Parkinson and Movement disorders Society; received research support from Merz-Pharma, Orkyn, Aguettant, Elivie, Ipsen, Everpharma, Fondation Desmarest, AMADYS, Fonds de Dotation Brou de Laurière, Agence Nationale de la Recherche; received travel grant from Vitalair, PEPS development, Aguettant, Merz-Pharma, Ipsen, Merck, Orkyn, Elivie, Adelia Medical, Dystonia Medical Research Foundation, International Parkinson and Movement disorders Society, European Academy of Neurology, International Association of Parkinsonism and Related Disorders. Dr. Couratier reports having received travel grant from Allergan, Novartis, Esai, UCB, Medtronic, Merck Serono, Biogen, LFB, Teva, Icomed, GSK, Genzyme, Aguettant, Cyberonics and Merz-Pharma. Dr. Lannuzel reports having received research support from France Parkinson, PSP France, Agence Nationale de la Recherche, Fonds Européen de DEveloppement Regional, French Ministry of Health, University Hospital of Guadeloupe, received honoraria for a speech from Association des Neurologues du Québec; received travel grant from Vitalair, PEPS development, Merz-Pharma, International Parkinson and Movement disorders Society. Dr. San-Galli, Dr. Martino, Dr. Carles, and Dr. Joguet report no disclosures.
Ethics approval
Not applicable.
Informed consent
Not applicable.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chaumont, H., San-Galli, A., Martino, F. et al. Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J Neurol 267, 3121–3127 (2020). https://doi.org/10.1007/s00415-020-09986-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-09986-y